In addition to intestinal cancer, LRG1 could act as the biomarker for esophagus cancer, gastric carcinoma, and bile duct cancer, etc. Overexpression of LRG1 negatively regulated TGF-β signaling pathways to inhibite cellular migration and invasion of esophageal squamous (Zhang N. et al., 2020). Here, LRG1 is linked to gastric carcinoma.